<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01014650</url>
  </required_header>
  <id_info>
    <org_study_id>GLYX13-C-101</org_study_id>
    <nct_id>NCT01014650</nct_id>
  </id_info>
  <brief_title>Single Ascending Dose Safety, Tolerability and Pharmacokinetics Study of GLYX-13 in Normal Volunteers</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Single Intravenous Dose, Ascending Dose Level Study of the Safety, Tolerability and Pharmacokinetics of GLYX-13 in Normal Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Naurex, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Naurex, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of a
      single IV dose of GLYX-13, an N-Methyl-D-aspartate (NMDA) receptor glycine site functional
      partial agonist, in normal, healthy human volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NMDA receptor glycine site partial agonists (GFPAs) have been demonstrated to be efficacious
      in animal models and/or in early human studies of several Central Nervous System (CNS)
      diseases including neuropathic pain, major depressive disorder, schizophrenia, Alzheimer's
      disease, anxiety including posttraumatic stress syndrome, and cognition in Down's syndrome
      and autism and others, without the psychomimetic side effects of NMDA receptor channel
      blockers. GLYX-13 has demonstrated a wide therapeutic ratio (500:1) between efficacy and side
      effects in animals. The purpose of this study is to evaluate the safety and pharmacokinetics
      of GLYX-13 following a single IV dose.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Observed and laboratory-confirmed safety</measure>
    <time_frame>four weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of parent drug will be assessed over time to estimate duration of pharmacodynamics in future efficacy trials. Plasma concentration and pharmacokinetics will be related in time to observed side effects.</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>IV normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single IV dose of normal saline as a control for safety and tolerability observations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV GLYX-13</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV dose of GLYX-13</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SC GLYX-13</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single SC dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLYX-13</intervention_name>
    <description>single IV or SC dose</description>
    <arm_group_label>IV GLYX-13</arm_group_label>
    <arm_group_label>SC GLYX-13</arm_group_label>
    <other_name>NMDA receptor glycine site partial agonist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV normal saline</intervention_name>
    <description>Single IV dose of normal saline</description>
    <arm_group_label>IV normal saline</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinical laboratory values &lt; 2x the upper limit of normal

          -  ability to understand the requirements of the study and provide informed consent

        Exclusion Criteria:

          -  alcohol abuse

          -  abuse of illicit substances

          -  current smoker

          -  currently taking prescription medications (other than for birth control)

          -  history of allergy to NMDA receptor ligands

          -  received another investigational drug within 30 days

          -  psychiatric disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil Singla, MD</last_name>
    <role>Study Director</role>
    <affiliation>Lotus Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lotus Clinical Research</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2009</study_first_submitted>
  <study_first_submitted_qc>November 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2009</study_first_posted>
  <last_update_submitted>February 18, 2016</last_update_submitted>
  <last_update_submitted_qc>February 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glycine site partial agonist</keyword>
  <keyword>normal volunteers</keyword>
  <keyword>safety in normal volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

